Video

Simple, readily available tests flag prognostic markers in CLL patients


 

Community Oncology Editor-in-Chief Dr. David Henry spoke with Dr. Jorge Cortes at the Oncology Practice Summit in Las Vegas about prognostic markers in chronic lymphocytic leukemia.

The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.

Recommended Reading

A Randomized, Controlled Trial of Panax quinquefolius Extract (CVT-E002) to Reduce Respiratory Infection in Patients With Chronic Lymphocytic Leukemia
MDedge Hematology and Oncology
Did you know: Dr. David Henry reports from ASH
MDedge Hematology and Oncology
Experimental CARS therapy breaks through relapsed CLL
MDedge Hematology and Oncology
Imatinib approved for children with Ph+ acute lymphoblastic leukemia
MDedge Hematology and Oncology
Treatment-related AML rises in non-Hodgkin's lymphoma
MDedge Hematology and Oncology
Genotyping yields clues to treatment-related toxicity and mortality
MDedge Hematology and Oncology
Bone marrow fibrosis reversal after use of hydroxyurea in a patient with myelofibrosis
MDedge Hematology and Oncology
POEMS syndrome: a significant clinical response to lenalidomide
MDedge Hematology and Oncology
Methotrexate-induced erythema multiforme
MDedge Hematology and Oncology
Company suspends enrollment in drug trials
MDedge Hematology and Oncology

Related Articles